Autors: Bryaskova R.G., Staykov, K. G., Ganchev, D. S.
Title: Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems
Keywords: cancer therapy, chemotherapeutics, drug release, nanomedicine, polymer micelles

Abstract: Polymeric micelles have become a versatile and clinically significant class of nanocarriers for cancer therapy. They effectively solubilize poorly water-soluble anticancer drugs, extend their circulation in the bloodstream, and promote accumulation in tumors. Early studies focused on conventional PEG-based polymeric micelles that utilize passive targeting based on the enhanced permeability and retention (EPR) effect, with several of these advancing to clinical trials. Active targeting strategies using modified polymer micelles with various targeting ligands have been introduced to enhance cellular uptake and improve tumor specificity. Recently, the field has shifted toward smart polymer micelles that can respond to both internal (endogenous) and external (exogenous) stimuli. These stimuli-responsive systems enable controlled drug release, enhance delivery inside cells, and improve therapeutic effectiveness, all while reducing systemic toxicity. This review summarizes recent advancements in polymer design, drug-loading techniques, preparation methods, and targeting strategies for polymeric micelles, highlighting both preclinical progress and systems that have reached clinical stages. The transition from conventional to smart polymer micelles is a significant advancement toward achieving more precise, effective, and personalized cancer nanomedicine.

References

  1. World Health Organization (WHO) International Agency for Research on Cancer (IARC) Global Cancer Burden 2022 WHO Geneva, Switzerland 2024 Available online: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services (accessed on 20 December 2025)
  2. American Association for Cancer Research AACR Cancer Progress Report 2025 AACR Philadelphia, PA, USA 2025
  3. Narvekar M. Xue H.Y. Eoh J.Y. Wong H.L. Nanocarrier for poorly water-soluble anticancer drugs—Barriers of translation and solutions AAPS PharmSciTech 2014 15 822 833 10.1208/s12249-014-0107-x
  4. Cabral H. Kataoka K. Multifunctional nanoassemblies of block copolymers for future cancer therapy Sci. Technol. Adv. Mater. 2010 11 014109 10.1088/1468-6996/11/1/014109 27877324
  5. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems J. Control. Release 2001 73 137 172 10.1016/S0168-3659(01)00299-1
  6. Kwon G.S. Kataoka K. Block copolymer micelles as long-circulating drug vehicles Adv. Drug Deliv. Rev. 2012 64 237 245 10.1016/j.addr.2012.09.016
  7. Allen T.M. Cullis P.R. Liposomal drug delivery systems: From concept to clinical applications Adv. Drug Deliv. Rev. 2013 65 36 48 10.1016/j.addr.2012.09.037
  8. Barenholz Y. Doxil®—The first FDA-approved nano-drug: Lessons learned J. Control. Release 2012 160 117 134 10.1016/j.jconrel.2012.03.020
  9. Kumari A. Yadav S.K. Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems Colloids Surf. B Biointerfaces 2010 75 1 18 10.1016/j.colsurfb.2009.09.001
  10. Kesharwani P. Jain K. Jain N.K. Dendrimer as nanocarrier for drug delivery Prog. Polym. Sci. 2014 39 268 307 10.1016/j.progpolymsci.2013.07.005
  11. Peer D. Karp J.M. Hong S. Farokhzad O.C. Margalit R. Langer R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007 2 751 760 10.1038/nnano.2007.387 18654426
  12. Grossen P. Witzigmann D. Sieber S. Huwyler J. PEG–PCL-Based Nanomedicines: A Biodegradable Drug Delivery System and Its Application J. Control. Release 2017 260 46 60 10.1016/j.jconrel.2017.05.028 28536049
  13. Danhier F. Feron O. Préat V. To Exploit the Tumor Microenvironment: Passive and Active Tumor Targeting of Nanocarriers for Anti-Cancer Drug Delivery J. Control. Release 2010 148 135 146 10.1016/j.jconrel.2010.08.027 20797419
  14. Xu M. Han X. Xiong H. Gao Y. Xu B. Zhu G. Li J. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials Molecules 2023 28 5145 10.3390/molecules28135145
  15. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity Adv. Drug Deliv. Rev. 2015 91 3 6 10.1016/j.addr.2015.01.002 25579058
  16. Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics Theranostics 2020 10 4557 4588 10.7150/thno.38069
  17. Zhu J. Al-Amili M. Guo S. Tumor microenvironment-responsive drug delivery based on polymeric micelles for precision cancer therapy Biomedicines 2024 12 417 10.3390/biomedicines12020417 38398021
  18. Yu G. Ning Q. Mo Z. Tang S. Intelligent polymeric micelles for multidrug co-delivery and cancer therapy Artif. Cells Nanomed. Biotechnol. 2019 47 1476 1487 10.1080/21691401.2019.1601104
  19. Sagar G.H. Arunagirinathan M.A. Bellare J.R. Self-assembled surfactant nano-structures important in drug delivery: A review Indian J. Exp. Biol. 2007 45 133 159
  20. Rajagopal K. Schneider J.P. Self-assembling peptides and proteins for nanotechnological applications Curr. Opin. Struct. Biol. 2004 14 480 486 10.1016/j.sbi.2004.06.006
  21. Branco M.C. Schneider J.P. Self-assembling materials for therapeutic delivery Acta Biomater. 2009 5 817 831 10.1016/j.actbio.2008.09.018
  22. Tu R.S. Tirrell M. Bottom-up design of biomimetic assemblies Adv. Drug Deliv. Rev. 2004 56 1537 1563 10.1016/j.addr.2003.10.047
  23. Kita-Tokarczyk J. Grumelard J. Haefele T. Meier W. Block copolymer vesicles—Using concepts from polymer chemistry to mimic biomembranes Polymer 2005 46 3540 3563 10.1016/j.polymer.2005.02.083
  24. Whitesides G.M. Grzybowski B. Self-assembly at all scales Science 2002 295 2418 2421 10.1126/science.1070821
  25. Wu X. Griffin P. Price G.J. Guy R.H. Preparation and in vitro evaluation of topical formulations based on polystyrene-poly-2-hydroxyl methacrylate nanoparticles Mol. Pharm. 2009 6 1449 1456 10.1021/mp900119u
  26. Hong S.W. Kim K.H. Huh J. Ahn C.-H. Jo W.H. Drug release behavior of poly(ε-caprolactone)-b-poly(acrylic acid) shell crosslinked micelles below the critical micelle concentration Macromol. Res. 2005 13 397 402 10.1007/BF03218472
  27. Cho H.K. Lone S. Kim D.D. Choi J.H. Choi S.W. Cho J.H. Kim J.H. Cheong I.W. Synthesis and characterization of fluorescein isothiocyanate (FITC)-labeled PEO–PCL–PEO triblock copolymers for topical delivery Polymer 2009 50 2357 2364 10.1016/j.polymer.2009.03.032
  28. Zha L.-S. Li L. Zhao H.-P. Preparation and characterization of nimodipine-loaded methoxy poly(ethylene glycol)-poly(lactic acid) diblock copolymer nanoparticles J. Donghua Univ. 2006 23 107 114 10.2147/IJN.S186899
  29. Hirao A. Goseki R. Ishizone T. Advances in living anionic polymerization: From functional monomers, polymerization systems, to macromolecular architectures Macromolecules 2014 47 1883 1905 10.1021/ma401175m
  30. Matyjaszewski K. Spanswick J. Controlled/living radical polymerization Mater. Today 2005 8 26 33 10.1016/S1369-7021(05)00745-5
  31. Mai Y. Eisenberg A. Self-assembly of block copolymers Chem. Soc. Rev. 2012 41 5969 5985 10.1039/c2cs35115c 22776960
  32. Riess G. Micellization of block copolymers Prog. Polym. Sci. 2003 28 1107 1170 10.1016/S0079-6700(03)00015-7
  33. Gohy J.-F. Block copolymer micelles Adv. Polym. Sci. 2005 190 65 136 10.1007/12_048
  34. Quemener D. Deratani A. Lecommandoux S. Dynamic assembly of block copolymers Top. Curr. Chem. 2012 322 165 192 10.1007/128_2011_258
  35. Kocak G. Tuncer C. Bütün V. pH-responsive polymers Polym. Chem. 2017 8 144 176 10.1039/C6PY01872F
  36. Doncom K.E.B. Blackman L.D. Wright D.B. Gibson M.I. O’Reilly R.K. Dispersity effects in polymer self-assemblies: A matter of hierarchical control Chem. Soc. Rev. 2017 46 4119 4134 10.1039/C6CS00818F
  37. Liu J. Lee H. Allen C. Formulation of drugs in block copolymer micelles: Drug loading and release Curr. Pharm. Des. 2006 12 4685 4701 10.2174/138161206779026263
  38. Gaucher G. Dufresne M.-H. Sant V.P. Kang N. Maysinger D. Leroux J.-C. Block copolymer micelles: Preparation, characterization and application in drug delivery J. Control. Release 2005 109 169 188 10.1016/j.jconrel.2005.09.034
  39. Karayianni M. Pispas S. Self-Assembly of Amphiphilic Block Copolymers in Selective Solvents Springer Series on Fluorescence 16 Springer International Publishing Cham, Switzerland 2016 27 63 10.1007/978-3-319-26788-3_2
  40. Kwon G.S. Okano T. Polymeric micelles as new drug carriers Adv. Drug Deliv. Rev. 1996 21 107 116 10.1016/S0169-409X(96)00401-2
  41. Lavasanifar A. Samuel J. Kwon G.S. Poly(ethylene oxide)–block–poly(L-amino acid) micelles for drug delivery Adv. Drug Deliv. Rev. 2002 54 169 190 10.1016/S0169-409X(02)00015-7 11897144
  42. Yang Z.L. Li X.R. Yang K.W. Liu Y. Amphotericin B-loaded poly(ethylene glycol)–poly(lactide) micelles: Preparation, freeze-drying, and in vitro release J. Biomed. Mater. Res. A 2008 85 539 546 10.1002/jbm.a.31504 17729259
  43. Cho S. Rasoulianboroujeni M. Kang R.H. Kwon G.S. From Conventional to Next-Generation Strategies: Recent Advances in Polymeric Micelle Preparation for Drug Delivery Pharmaceutics 2025 17 1360 10.3390/pharmaceutics17101360
  44. Scholz N. Behnke T. Resch-Genger U. Determination of the critical micelle concentration of neutral and ionic surfactants with fluorometry, conductometry, and surface tension-A method comparison J. Fluoresc. 2018 28 465 476 10.1007/s10895-018-2209-4
  45. Rosen M.J. Kunjappu J.T. Surfactants and Interfacial Phenomena 4th ed. Wiley Hoboken, NJ, USA 2012
  46. Ghezzi M. Pescina S. Padula C. Santi P. Del Favero E. Cantù L. Nicoli S. Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions Pharmaceutics 2021 13 197 10.1016/j.jconrel.2021.02.031
  47. Schärtl W. Light Scattering from Polymer Solutions and Nanoparticle Dispersions Springer Berlin/Heidelberg, Germany 2007
  48. Bryaskova R. Georgiev N. Philipova N. Bakov V. Anichina K. Argirova M. Apostolova S. Georgieva I. Tzoneva R. Novel fluorescent benzimidazole-hydrazone-loaded micellar carriers for controlled release: Impact on cell toxicity, nuclear and microtubule alterations in breast cancer cells Pharmaceutics 2023 15 1753 10.3390/pharmaceutics15061753
  49. Gao M. Yang Y. Bergfel A. Huang L. Zheng L. Bowden T.M. Self-assembly of cholesterol end-capped polymer micelles for controlled drug delivery J. Nanobiotechnol. 2020 18 13 10.1186/s12951-020-0575-y 31941501
  50. Kuntsche J. Horst J.C. Bunjes H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems Int. J. Pharm. 2011 417 120 137 10.1016/j.ijpharm.2011.02.001 21310225
  51. Zhong S. Pochan D.J. Cryogenic transmission electron microscopy for direct observation of polymer and small-molecule materials and structures in solution Polym. Rev. 2010 50 287 320 10.1080/15583724.2010.493254
  52. Esselink F.J. Dormidontova E. Hadziioannou G. Evolution of block copolymer micellar size and structure evidenced with cryo electron microscopy Macromolecules 1998 31 2925 2932 10.1021/ma971011o
  53. Lam Y.M. Grigorieff N. Goldbeck-Wood G. Direct visualization of micelles of Pluronic block copolymers in aqueous solution by cryo-TEM Phys. Chem. Chem. Phys. 1999 1 3331 3334 10.1039/a902369k
  54. Fairley N. Hoang B. Allen C. Morphological control of poly(ethylene glycol)-block-poly(ε-caprolactone) copolymer aggregates in aqueous solution Biomacromolecules 2008 9 2283 2291 10.1021/bm800572p
  55. Li T. Nowell C.J. Cipolla D. Rades T. Boyd B.J. Direct comparison of standard transmission electron microscopy and cryogenic-TEM in imaging nanocrystals inside liposomes Mol. Pharm. 2019 16 1775 1781 10.1021/acs.molpharmaceut.8b01308 30810323
  56. Jalili N. Laxminarayana K. A review of atomic force microscopy imaging systems: Application to molecular metrology and biological sciences Mechatronics 2004 14 907 945 10.1016/j.mechatronics.2004.04.005
  57. Kotta S. Aldawsari H.M. Badr-Eldin S.M. Nair A.B. YT K. Progress in Polymeric Micelles for Drug Delivery Applications Pharmaceutics 2022 14 1636 10.3390/pharmaceutics14081636
  58. Pedersen J.S. Svaneborg C. Scattering from block copolymer micelles Curr. Opin. Colloid Interface Sci. 2002 7 158 166 10.1016/S1359-0294(02)00044-4
  59. Chen T. He B. Tao J. He Y. Deng H. Wang X. Zheng Y. Application of Förster resonance energy transfer (FRET) technique to elucidate intracellular and in vivo biofate of nanomedicines Adv. Drug Deliv. Rev. 2019 143 177 205 10.1016/j.addr.2019.04.009 31201837
  60. Qiu L. Zheng C. Jin Y. Zhu K. Polymeric micelles as nanocarriers for drug delivery Expert Opin. Ther. Pat. 2007 17 819 830 10.1517/13543776.17.7.819
  61. Nishiyama N. Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery Pharmacol. Ther. 2006 112 630 648 10.1016/j.pharmthera.2006.05.006
  62. Kataoka K. Harada A. Nagasaki Y. Block copolymer micelles for drug delivery: Design, characterization, and biological significance Adv. Drug Deliv. Rev. 2012 64 37 48 10.1016/j.addr.2012.09.013
  63. Oerlemans C. Bult W. Bos M. Storm G. Nijsen J.F. Hennink W.E. Polymeric micelles in anticancer therapy: Targeting, imaging and triggered release Pharm. Res. 2010 27 2569 2589 10.1007/s11095-010-0233-4
  64. National Institute of Diabetes and Digestive and Kidney Diseases LiverTox: Clinical and Research Information on Drug-Induced Liver Injury National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD, USA 2012 31643176
  65. Gelderblom H. Verweij J. Nooter K. Sparreboom A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 2001 37 1590 1598 10.1016/S0959-8049(01)00171-X
  66. Kim S.C. Kim D.W. Shim Y.H. Bang Y.J. Oh H.S. Kim S.W. Seo M.H. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy J. Control. Release 2001 72 191 202 10.1016/S0168-3659(01)00275-9
  67. Ahn H.K. Jung M. Sym S.J. Shin D.B. Kang S.M. Kyung S.Y. Park J.W. Jeong S.H. Cho E.K. A phase II trial of Cremophor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer Cancer Chemother. Pharmacol. 2014 74 277 282 10.1007/s00280-014-2498-5
  68. Kim T.Y. Kim D.W. Chung J.Y. Shin S.G. Kim S.C. Heo D.S. Kim N.K. Bang Y.J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free polymeric micelle formulation of paclitaxel Clin. Cancer Res. 2004 10 3708 3716 10.1158/1078-0432.CCR-03-0655
  69. Lee S.-W. Yun M.-H. Jeong S.W. In C.-H. Kim J.-Y. Seo M.-H. Pai C.-M. Kim S.-O. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system J. Control. Release 2011 155 262 271 10.1016/j.jconrel.2011.06.012
  70. Hamaguchi T. Matsumura Y. Suzuki M. Shimizu K. Goda R. Nakamura I. Nakatomi I. Yokoyama M. Kataoka K. Kakizoe T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 2005 92 1240 1246 10.1038/sj.bjc.6602479
  71. Hamaguchi T. Kato K. Yasui H. Morizane C. Ikeda M. Ueno H. Muro K. Yamada Y. Okusaka T. Shirao K. et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation Br. J. Cancer 2007 97 170 176 10.1038/sj.bjc.6603855
  72. Mukai H. Kato K. Esaki T. Ohsumi S. Hozomi Y. Matsubara N. Hamaguchi T. Marsumura Y. Goda R. Hirai T. et al. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors Investig. New Drugs 2016 34 750 759 10.1007/s10637-016-0381-4 27595901
  73. Gou M. Wei X. Men K. Wang B. Luo F. Zhao X. Wei Y. Qian Z. PCL/PEG copolymeric nanoparticles: Potential nanoplatforms for anticancer agent delivery Curr. Drug Targets 2011 12 1131 1150 10.2174/138945011795906642
  74. Cabral H. Miyata K. Osada K. Kataoka K. Block copolymer micelles in nanomedicine applications Chem. Rev. 2018 118 6844 6892 10.1021/acs.chemrev.8b00199 29957926
  75. Shariff S.H.A. Wan Abdul Khodir W.K. Abd Hamid S. Haris M.S. Ismail M.W. Poly(caprolactone)-b-poly(ethylene glycol)-Based Polymeric Micelles as Drug Carriers for Efficient Breast Cancer Therapy: A Systematic Review Polymers 2022 14 4847 10.3390/polym14224847
  76. Cho H. Lai T.C. Kwon G.S. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: Evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer J. Control. Release 2013 166 1 9 10.1016/j.jconrel.2012.12.005
  77. Jin M.J. Piao S.J. Jin T.X. Jin Z.H. Yin X.Z. Gao Z.G. Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles J. Huazhong Univ. Sci. Technolog. Med. Sci. 2014 34 66 75 10.1007/s11596-014-1233-0
  78. Cortés-Funes H. Coronado C. Role of anthracyclines in the era of targeted therapy Cardiovasc. Toxicol. 2007 7 56 60 10.1007/s12012-007-0015-3
  79. Rahman A.M. Yusuf S.W. Ewer M.S. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation Int. J. Nanomed. 2007 2 567 583
  80. Sritharan S. Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin Life Sci. 2021 278 119527 10.1016/j.lfs.2021.119527 33887349
  81. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem. Pharmacol. 1999 57 727 741 10.1016/S0006-2952(98)00307-4 10075079
  82. Ogura M. Adriamycin (doxorubicin) Gan Kagaku Ryoho 2001 28 1331 1338 (In Japanese)
  83. Diao Y.Y. Li H.Y. Fu Y.H. Han M. Hu Y.L. Jiang H.L. Tsutsumi Y. Wei Q.C. Chen D.W. Gao J.Q. Doxorubicin-loaded PEG–PCL copolymer micelles enhance cytotoxicity and intracellular accumulation of doxorubicin in adriamycin-resistant tumor cells Int. J. Nanomed. 2011 6 1955 1962 10.2147/IJN.S23099
  84. Cuong N.V. Jiang J.L. Li Y.L. Chen J.R. Jwo S.C. Hsieh M.F. Doxorubicin-loaded PEG–PCL–PEG micelle using xenograft model of nude mice: Effect of multiple administration of micelle on the suppression of human breast cancer Cancers 2010 3 61 78 10.3390/cancers3010061
  85. Zhang J. Men K. Gu Y. Wang X. Gou M. Guo G. Luo F. Qian Z. Preparation of core cross-linked PCL–PEG–PCL micelles for doxorubicin delivery in vitro J. Nanosci. Nanotechnol. 2011 11 5054 5061 10.1166/jnn.2011.4121
  86. Kelland L. The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 2007 7 573 584 10.1038/nrc2167
  87. Piccart M.J. Lamb H. Vermorken J.B. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer Ann. Oncol. 2001 12 1195 1203 10.1023/A:1012259625746 11697824
  88. Hartmann J.T. Lipp H.-P. Toxicity of platinum compounds Expert Opin. Pharmacother. 2003 4 889 901 10.1517/14656566.4.6.889 12783586
  89. Nishiyama N. Kataoka K. Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core J. Control. Release 2001 74 83 94 10.1016/S0168-3659(01)00314-5
  90. Nishiyama N. Okazaki S. Cabral H. Miyamoto M. Kato Y. Sugiyama Y. Nishio K. Matsumura Y. Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 2003 63 8977 8983 14695216
  91. Plummer R. Wilson R.H. Calvert H. Boddy A.V. Griffin M. Sludden J. Tilby M.J. Eatock M. Pearson D.G. Ottley C.J. et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Br. J. Cancer 2011 104 593 598 10.1038/bjc.2011.6
  92. Uchino H. Matsumura Y. Negishi T. Koizumi F. Hayashi T. Honda T. Nishiyama N. Kataoka K. Naito S. Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 2005 93 678 687 10.1038/sj.bjc.6602772
  93. Duan X. He C. Kron S.J. Lin W. Nanoparticle formulations of cisplatin for cancer therapy Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016 8 776 791 10.1002/wnan.1390
  94. Wang X. Guo Z. Targeting and delivery of platinum-based anticancer drugs Chem. Soc. Rev. 2013 42 202 224 10.1039/C2CS35259A
  95. Cabral H. Nishiyama N. Kataoka K. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity J. Control. Release 2007 121 146 155 10.1016/j.jconrel.2007.05.024
  96. Rafi M. Cabral H. Kano M.R. Mi P. Iwata C. Yashiro M. Hirakawa K. Miyazono K. Nishiyama N. Kataoka K. Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum(II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis J. Control. Release 2011 152 59 66 10.1016/j.jconrel.2012.01.038
  97. Kim J. Pramanick S. Lee D. Park H. Kim W.J. Polymeric biomaterials for the delivery of platinum-based anticancer drugs Biomater. Sci. 2015 3 1002 1017 10.1039/C5BM00039D
  98. Oberoi H.S. Nukolova N.V. Laquer F.C. Poluektova L.Y. Huang J. Alnouti Y. Yokohira M. Arnold L.L. Kabanov A.V. Cohen S.M. et al. Cisplatin-loaded core cross-linked micelles: Comparative pharmacokinetics, antitumor activity, and toxicity in mice Int. J. Nanomed. 2012 7 2557 2571 10.2147/IJN.S29145
  99. Yakkala P.A. Penumallu N.R. Shafi S. Kamal A. Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents Pharmaceuticals 2023 16 1456 10.3390/ph16101456 37895927
  100. Pérez-Ortega H.U. Córdova-Espíritu R.R. Cano-Serrano S. García-González E. Bravo-Sánchez M.G. Orozco-Mosqueda M.d.C. Jiménez-Islas H. Luna-Bárcenas G. Villaseñor-Ortega F. Camptothecin in cancer therapy: Current challenges and emerging strategies with nanoemulsions Pharmaceutics 2025 17 1414 10.3390/pharmaceutics17111414 41304752
  101. Watanabe M. Kawano K. Yokoyama M. Opanasopit P. Okano T. Maitani Y. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability Int. J. Pharm. 2006 308 183 189 10.1016/j.ijpharm.2005.10.030
  102. Tan C. Wang Y. Fan W. Exploring polymeric micelles for improved delivery of anticancer agents: Recent developments in preclinical studies Pharmaceutics 2013 5 201 219 10.3390/pharmaceutics5010201
  103. Malhotra S. Dumoga S. Joshi A. Mohanty S. Singh N. Polymeric micelles coated with hybrid nanovesicles enhance the therapeutic potential of the reversible topoisomerase inhibitor camptothecin in a mouse model Acta Biomater. 2021 121 579 591 10.1016/j.actbio.2020.11.049
  104. Gu Q. Xing J.Z. Huang M. He C. Chen J. SN 38 loaded polymeric micelles to enhance cancer therapy Nanotechnology 2012 23 205101 10.1088/0957-4484/23/20/205101
  105. Gou M. Men K. Shi H. Xiang M. Zhang J. Song J. Long J. Wan Y. Luo F. Zhao X. et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo Nanoscale 2011 3 1558 1567 10.1039/c0nr00758g
  106. Zhu W.T. Liu S.Y. Wu L. Xu H.L. Wang J. Ni G.X. Zeng Q.B. Delivery of curcumin by directed self-assembled micelles enhances therapeutic treatment of non-small-cell lung cancer Int. J. Nanomed. 2017 12 2621 2634 10.2147/IJN.S128921
  107. Kumari P. Swami M.O. Nadipalli S.K. Myneni S. Ghosh B. Biswas S. Curcumin delivery by poly(lactide)-based co-polymeric micelles: An in vitro anticancer study Pharm. Res. 2016 33 826 841 10.1007/s11095-015-1830-z
  108. Wang J. Ma W. Tu P. Synergistically improved anti-tumor efficacy by co-delivery doxorubicin and curcumin polymeric micelles Macromol. Biosci. 2015 15 1252 1261 10.1002/mabi.201500043
  109. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging AAPS J. 2007 9 E128 E147 10.1208/aapsj0902015
  110. Li W. Szoka F.C. Jr. Lipid-based nanoparticles for nucleic acid delivery Pharm. Res. 2007 24 438 449 10.1007/s11095-006-9180-5
  111. Kim S.H. Jeong J.H. Chun K.W. Park T.G. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate Langmuir 2005 21 8852 8857 10.1021/la0502084 16142970
  112. Park E.K. Kim S.Y. Lee S.B. Lee Y.M. Folate-conjugated methoxy poly(ethylene glycol)/poly(ε-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery J. Control. Release 2005 109 158 168 10.1016/j.jconrel.2005.09.039
  113. Yoo H.S. Park T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles J. Control. Release 2004 96 273 283 10.1016/j.jconrel.2004.02.003
  114. Zhao H. Yung L.Y.L. Selectivity of folate conjugated polymer micelles against different tumor cells Int. J. Pharm. 2008 349 256 268 10.1016/j.ijpharm.2007.07.040 17850996
  115. He Z. Huang J. Xu Y. Zhang X. Teng Y. Huang C. Wu Y. Zhang X. Zhang H. Sun W. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small cell lung cancer Oncotarget 2015 6 42150 42168 10.18632/oncotarget.6243
  116. Han X. Liu J. Liu M. Xie C. Zhan C. Gu B. Liu Y. Feng L. Lu W. 9-NC-loaded folate-conjugated polymer micelles as tumor-targeted drug delivery systems: Preparation and in vitro evaluation Int. J. Pharm. 2009 372 125 131 10.1016/j.ijpharm.2008.12.035 19166923
  117. Kessler H. Diefenbach B. Finsinger D. Geyer A. Gurrath M. Goodman S.L. Hölzemann G. Haubner R. Jonczyk A. Müller G. et al. Design of superactive and selective integrin receptor antagonists containing the RGD sequence Lett. Pept. Sci. 1995 2 155 160 10.1007/BF00119142
  118. Haubner R. Gratias R. Diefenbach B. Goodman S.L. Jonczyk A. Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists J. Am. Chem. Soc. 1996 118 7461 7472 10.1021/ja9603721
  119. Wu X. Reddy D.S. Integrins as receptor targets for neurological disorders Pharmacol. Ther. 2012 134 68 81 10.1016/j.pharmthera.2011.12.008
  120. Desgrosellier J.S. Cheresh D.A. Integrins in cancer: Biological implications and therapeutic opportunities Nat. Rev. Cancer 2010 10 9 22 10.1038/nrc2748
  121. Nasongkla N. Shuai X. Ai H. Weinberg B.D. Pink J. Boothman D.A. Gao J. cRGD-functionalized polymer micelles for targeted doxorubicin delivery Angew. Chem. Int. Ed. 2004 43 6323 6327 10.1002/anie.200460800
  122. Zhan C. Gu B. Xie C. Li J. Liu Y. Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect J. Control. Release 2010 143 136 142 10.1016/j.jconrel.2009.12.020
  123. Zhao L. Yang C. Dou J. Xi Y. Lou H. Zhai G. Development of RGD-functionalized PEG-PLA micelles for delivery of curcumin J. Biomed. Nanotechnol. 2015 11 436 446 10.1166/jbn.2015.1919 26307827
  124. Daniels T.R. Bernabeu E. Rodríguez J.A. Patel S. Kozman M. Chiappetta D.A. Holler E. Ljubimova J.Y. Helguera G. Penichet M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer Biochim. Biophys. Acta 2012 1820 291 317 10.1016/j.bbagen.2011.07.016 21851850
  125. Yue J. Liu S. Wang R. Hu X. Xie Z. Huang Y. Jing X. Transferrin-Conjugated Micelles: Enhanced Accumulation and Antitumor Effect for Transferrin-Receptor-Overexpressing Cancer Models Mol. Pharm. 2012 9 1919 1931 10.1021/mp300213g
  126. Sun P. Xiao Y. Di Q. Ma W. Ma X. Wang Q. Chen W. Transferrin Receptor-Targeted PEG-PLA Polymeric Micelles for Chemotherapy Against Glioblastoma Multiforme Int. J. Nanomed. 2020 15 6673 6688 10.2147/IJN.S257459
  127. Torchilin V.P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery Biopolymers 2008 90 604 610 10.1002/bip.20989
  128. Iakoubov L.Z. Torchilin V.P. A novel class of antitumor antibodies: Nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice Oncol. Res. 1997 9 439 446
  129. Sawant R.R. Torchilin W. Polymeric micelles: Polyethylene glycol–phosphatidylethanolamine (PEG–PE)-based micelles as an example Cancer Nanotechnology: Methods and Protocols Humana Press Totowa, NJ, USA 2010 Volume 624 131 149 10.1007/978-1-60761-609-2_9
  130. Jin C. Qian N. Zhao W. Yang W. Bai L. Wu H. Dou K. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F (ab′) 2 for hepatocellular carcinoma Biomacromolecules 2010 11 2422 2431 10.1021/bm1005992
  131. Jhawer M. Goel S. Wilson A.J. Montagna C. Ling Y.H. Byun D.S. Nasser S. Arango D. Shin J. Klampfer L. et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res. 2008 68 1953 1961 10.1158/0008-5472.CAN-07-5659
  132. Zeng F. Lee H. Allen C. Epidermal growth factor-conjugated poly(ethylene glycol)-block-poly(δ-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics Bioconjug. Chem. 2006 17 399 409 10.1021/bc050350g 16536472
  133. Noh T. Kook Y.H. Park C. Youn H. Kim H. Oh E.T. Choi E.K. Park H.J. Kim C. Block copolymer micelles conjugated with anti-EGFR antibody for targeted delivery of anticancer drug J. Polym. Sci. Part A Polym. Chem. 2008 46 7321 7331 10.1002/pola.23036
  134. Ellington A.D. Szostak J.W. In vitro selection of RNA molecules that bind specific ligands Nature 1990 346 818 822 10.1038/346818a0 1697402
  135. Nimjee S.M. Rusconi C.P. Sullenger B.A. Aptamers: An emerging class of therapeutics Annu. Rev. Med. 2005 56 555 583 10.1146/annurev.med.56.062904.144915
  136. Farokhzad O.C. Cheng J. Teply B.A. Sherifi I. Jon S. Kantoff P.W. Richie J.P. Langer R. Targeted nanoparticle–aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. USA 2006 103 6315 6320 10.1073/pnas.0601755103 16606824
  137. Dhar S. Gu F.X. Langer R. Farokhzad O.C. Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer-functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. USA 2008 105 17356 17361 10.1073/pnas.0809154105
  138. Fu S. Zhu X. Huang F. Chen X. Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization Pharmaceutics 2025 17 1074 10.3390/pharmaceutics17081074
  139. Hira S.K. Mishra A.K. Ray B. Manna P.P. Targeted Delivery of Doxorubicin-Loaded Poly (ε-caprolactone)-b-Poly (N-vinylpyrrolidone) Micelles Enhances Antitumor Effect in Lymphoma PLoS ONE 2014 9 e94309 10.1371/journal.pone.0094309
  140. Le Garrec D. Gori S. Luo L. Lessard D. Smith D.C. Yessine M.A. Ranger M. Leroux J.-C. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a New Polymeric Solubilizer for Hydrophobic Anticancer Drugs: In Vitro and In Vivo Evaluation J. Control. Release 2004 99 83 101 10.1016/j.jconrel.2004.06.018
  141. Kang N. Leroux J.-C. Triblock and star-block copolymers of N-(2-hydroxypropyl) methacrylamide or N-vinyl-2-pyrrolidone and d,l-lactide: Synthesis and self-assembling properties in water Polymer 2004 45 8967 8980 10.1016/j.polymer.2004.10.081
  142. Zhu Z. Li Y. Li X. Li R. Jia Z. Liu B. Guo W. Wu W. Jiang X. Paclitaxel-Loaded Poly(N-vinylpyrrolidone)-b-Poly(ε-caprolactone) Nanoparticles: Preparation and Antitumor Activity In Vivo J. Control. Release 2010 142 438 446 10.1016/j.jconrel.2009.11.002
  143. Veeren A. Bhaw-Luximon A. Mukhopadhyay D. Jhurry D. Mixed poly(vinyl pyrrolidone)-based drug-loaded nanomicelles show enhanced efficacy against pancreatic cancer cell lines Eur. J. Pharm. Sci. 2017 102 250 260 10.1016/j.ejps.2017.03.021
  144. Luan F. He X. Zeng N. Tetrandrine: A review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems J. Pharm. Pharmacol. 2020 72 1491 1512 10.1111/jphp.13339
  145. Xu H. Hou Z. Zhang H. Kong H. Li X. Wang H. Xie W. An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion Int. J. Nanomed. 2014 9 231 242 10.2147/IJN.S55541
  146. Kuskov A.N. Voskresenskaya A.A. Goryachaya A.V. Artyukhov A.A. Shtilman M.I. Tsatsakis A.M. Preparation and characterization of amphiphilic poly-N-vinylpyrrolidone nanoparticles containing indomethacin J. Mater. Sci. Mater. Med. 2010 21 1521 1530 10.1007/s10856-010-4029-1
  147. Luss A.L. Kulikov P.P. Romme S.B. Andersen C.L. Pennisi C.P. Docea A.O. Kuskov A.N. Velonia K. Mezhuev Y.O. Shtilman M.I. et al. Nanosized carriers based on amphiphilic poly-N-vinyl-2-pyrrolidone for intranuclear drug delivery Nanomedicine 2018 13 703 715 10.2217/nnm-2017-0311 29629829
  148. Sandra F. Degli Esposti M. Ndebele K. Gona P. Knight D. Rosenquist M. Khosravi-Far R. Tumor necrosis factor-related apoptosis-inducing ligand alters mitochondrial membrane lipids Cancer Res. 2005 65 8286 8297 10.1158/0008-5472.CAN-04-1913
  149. Yagolovich A. Kuskov A. Kulikov P. Kurbanova L. Bagrov D. Artykov A. Gasparian M. Sizova S. Oleinikov V. Gileva A. et al. Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells Pharmaceutics 2021 13 1413 10.3390/pharmaceutics13091413
  150. Kukovyakina E.V. Kulikov P.P. Bagrov D.V. Moiseenko A.V. Trifonova T.S. Isakova A.A. Shuvalova M.L. Svirshchevskaya E.V. Khan I.I. Pokrovsky V.S. et al. Codelivery of bortezomib and modified DR5-selective TRAIL via amphiphilic poly(N-vinylpyrrolidone) bionanocomposites to overcome glioblastoma resistance ACS Appl. Bio Mater. 2025 8 10965 10978 10.1021/acsabm.5c01651
  151. Kukovyakina E. Isakova A.A. Bagrov D. Gasparian M. Kuskov A. Yagolovich A. Amphiphilic poly(N-vinylpyrrolidone) biocomposites with bortezomib and DR5-selective TRAIL variants: A promising approach to pancreatic cancer treatment Int. J. Mol. Sci. 2025 26 11620 10.3390/ijms262311620
  152. Liu Y. Wang W. Yang J. Zhou C. Sun J. pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery Asian J. Pharm. Sci. 2013 8 159 167 10.1016/j.ajps.2013.07.021
  153. Gao G.H. Li Y. Lee D.S. Environmental pH-sensitive polymeric micelles for cancer diagnosis and targeted therapy J. Control. Release 2013 169 180 184 10.1016/j.jconrel.2012.11.012 23195533
  154. Ofridam F. Tarhini M. Lebaz N. Gagnière É. Mangin D. Elaissari A. pH-sensitive polymers: Classification and some fine potential applications Polym. Adv. Technol. 2021 32 1455 1484 10.1002/pat.5230
  155. Tang H. Zhao W. Yu J. Li Y. Zhao C. Recent development of pH-responsive polymers for cancer nanomedicine Molecules 2019 24 4 10.3390/molecules24010004
  156. Zhang Y. Kim I. Lu Y. Xu Y. Yu D.-G. Song W. Intelligent poly(L-histidine)-based nanovehicles for controlled drug delivery J. Control. Release 2022 349 963 982 10.1016/j.jconrel.2022.08.005 35944751
  157. Lee E.S. Na K. Bae Y.H. Polymeric micelle for tumor pH and folate-mediated targeting J. Control. Release 2003 91 103 113 10.1016/S0168-3659(03)00239-6
  158. Lee E.S. Na K. Bae Y.H. Super pH-sensitive multifunctional polymeric micelle Nano Lett. 2005 5 325 329 10.1021/nl0479987 15794620
  159. Lee E.S. Na K. Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of multidrug resistance J. Control. Release 2005 103 405 418 10.1016/j.jconrel.2004.12.018
  160. Oh K.T. Yin H. Lee E.S. Bae Y.H. Polymeric nanovehicles for anticancer drugs with triggering release mechanisms J. Mater. Chem. 2007 17 3987 4001 10.1039/b707142f
  161. Lee E.S. Oh K.T. Kim D. Youn Y.S. Bae Y.H. Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine) J. Control. Release 2007 123 19 26 10.1016/j.jconrel.2007.08.006 17826863
  162. Gao Z.-G. Tian L. Hu J. Park I.-S. Bae Y.H. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles J. Control. Release 2011 152 84 89 10.1016/j.jconrel.2011.01.021 21295088
  163. Kim D. Gao Z.G. Lee E.S. Bae Y.H. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer Mol. Pharm. 2009 6 1353 1362 10.1021/mp900021q
  164. Tsai H.C. Chang W.H. Lo C.L. Tsai C.H. Chang C.H. Ou T.W. Yen T.C. Hsiue G.H. Graft and diblock copolymer multifunctional micelles for cancer chemotherapy and imaging Biomaterials 2010 31 2293 2301 10.1016/j.biomaterials.2009.11.059
  165. Zhou X.X. Jin L. Qi R.Q. Ma T. pH-responsive polymeric micelles self-assembled from amphiphilic copolymer modified with lipid used as doxorubicin delivery carriers R. Soc. Open Sci. 2018 5 171654 10.1098/rsos.171654
  166. Ko J. Park K. Kim Y.-S. Kim M.S. Han J.K. Kim K. Park R.-W. Kim I.-S. Song H.K. Lee D.S. et al. Tumoral acidic extracellular pH targeting of pH-responsive MPEG–poly(β-amino ester) block copolymer micelles for cancer therapy J. Control. Release 2007 123 109 115 10.1016/j.jconrel.2007.07.012
  167. Min K.H. Kim J.-H. Bae S.M. Shin H. Kim M.S. Park S. Lee H. Park R.-W. Kim I.-S. Kim K. et al. Tumoral acidic pH-responsive MPEG-poly(β-amino ester) polymeric micelles for cancer targeting therapy J. Control. Release 2010 144 259 266 10.1016/j.jconrel.2010.02.024
  168. Zhang C.Y. Yang Y.Q. Huang T.X. Zhao B. Guo X.D. Wang J.F. Zhang L.J. Self-assembled pH-responsive MPEG-b-(PLA-co-PAE) block copolymer micelles for anticancer drug delivery Biomaterials 2012 33 6273 6283 10.1016/j.biomaterials.2012.05.025 22695069
  169. Zhang C.Y. Xiong D. Sun Y. Zhao B. Lin W.J. Zhang L.J. Self-Assembled Micelles Based on pH-Sensitive PAE-g-MPEG-Cholesterol Block Copolymer for Anticancer Drug Delivery Int. J. Nanomed. 2014 9 4923 4933 10.2147/IJN.S69493 25364250
  170. Zhao H. Li Q. Hong Z. Paclitaxel-loaded mixed micelles enhance ovarian cancer therapy through extracellular pH-triggered PEG detachment and endosomal escape Mol. Pharm. 2016 13 2411 2422 10.1021/acs.molpharmaceut.6b00164
  171. Xu Z. Xue P. Gao Y.-E. Liu S. Shi X. Hou M. Kang Y. pH-responsive polymeric micelles based on poly(ethylene glycol)-b-poly(2-(diisopropylamino)ethyl methacrylate) block copolymer for enhanced intracellular release of anticancer drugs J. Colloid Interface Sci. 2017 490 511 519 10.1016/j.jcis.2016.11.091
  172. Yu P. Yu H. Guo C. Cui Z. Chen X. Yin Q. Zhang P. Yang X. Cui H. Li Y. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles Acta Biomater. 2015 14 115 124 10.1016/j.actbio.2014.12.001
  173. Gao Y.-E. Ma X. Hou M. Bai S. Xue P. Kang Y. Xu Z. Highly cell-penetrating and ultra-pH-responsive nanoplatform for controlled drug release and enhanced tumor therapy Colloids Surf. B Biointerfaces 2017 159 484 492 10.1016/j.colsurfb.2017.08.018 28841498
  174. Fife T.H. Jao L.K. General base catalysis in ester hydrolysis J. Org. Chem. 1965 30 1492 1495 10.1021/jo01016a036
  175. Gu Y. Zhong Y. Meng F. Cheng R. Deng C. Zhong Z. Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy Biomacromolecules 2013 14 2772 2780 10.1021/bm400615n
  176. Zhai Y. Zhou X. Jia L. Ma C. Song R. Deng Y. Hu X. Sun W. Acetal-linked paclitaxel polymeric prodrug based on functionalized mPEG-PCL diblock polymer for pH-triggered drug delivery Polymers 2017 9 698 10.3390/polym9120698
  177. Zielonka J. Joseph J. Sikora A. Hardy M. Ouari O. Vasquez-Vivar J. Cheng G. Lopez M. Kalyanaraman B. Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications Chem. Rev. 2017 117 10043 10120 10.1021/acs.chemrev.7b00042
  178. Chen Z.-P. Li M. Zhang L.-J. Wang J.-J. Wang X.-H. Guo J.-J. Zhang Y.-Z. Mitochondria-targeted drug delivery system for cancer treatment J. Drug Target. 2016 24 492 502 10.3109/1061186X.2015.1108325
  179. Zhong X.C. Xu W.H. Wang Z.T. Guo W.W. Chen J.J. Guo N.N. Gao J.Q. Doxorubicin derivative-loaded acetal-PEG-PCCL micelles for overcoming multidrug resistance in MCF-7/ADR cells Drug Dev. Ind. Pharm. 2019 45 1556 1564 10.1080/03639045.2019.1640721
  180. Yoo H.S. Lee E.A. Park T.G. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages J. Control. Release 2002 82 17 27 10.1016/S0168-3659(02)00088-3 12106973
  181. Bae Y. Fukushima S. Harada A. Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change Angew. Chem. Int. Ed. 2003 42 4640 4643 10.1002/anie.200250653 14533151
  182. Hu X. Liu S. Huang Y. Chen X. Jing X. Biodegradable block copolymer–doxorubicin conjugates via different linkages: Preparation, characterization, and in vitro evaluation Biomacromolecules 2010 11 2094 2102 10.1021/bm100458n
  183. Harada M. Bobe I. Saito H. Shibata N. Tanaka R. Hayashi T. Kato Y. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300 Cancer Sci. 2011 102 192 199 10.1111/j.1349-7006.2010.01745.x
  184. Takahashi A. Yamamoto Y. Yasunaga M. Koga Y. Kuroda J. Takigahira M. Harada M. Saito H. Hayashi T. Kato Y. et al. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin Cancer Sci. 2013 104 920 925 10.1111/cas.12153
  185. Alani A.W.G. Bae Y. Rao D.A. Kwon G.S. Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel Biomaterials 2010 31 1765 1772 10.1016/j.biomaterials.2009.11.038
  186. Han Y. Pan J. Liang N. Gong X. Sun S. A pH-sensitive polymeric micellar system based on chitosan derivative for efficient delivery of paclitaxel Int. J. Mol. Sci. 2021 22 6659 10.3390/ijms22136659 34206347
  187. Lanzalaco S. Armelin E. Poly(N-isopropylacrylamide) and Copolymers: A Review on Recent Progresses in Biomedical Applications Gels 2017 3 36 10.3390/gels3040036
  188. Wei H. Cheng S.-X. Zhang X.-Z. Zhuo R.-X. Thermo-sensitive polymeric micelles based on poly(N-isopropylacrylamide) as drug carriers Prog. Polym. Sci. 2009 34 893 910 10.1016/j.progpolymsci.2009.05.002
  189. Chilkoti A. Dreher M.R. Meyer D.E. Raucher D. Targeted drug delivery by thermally responsive polymers Adv. Drug Deliv. Rev. 2002 54 613 630 10.1016/S0169-409X(02)00041-8
  190. Batrakova E.V. Kabanov A.V. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers J. Control. Release 2008 130 98 106 10.1016/j.jconrel.2008.04.013
  191. Heskins M. Guillet J.E. Solution properties of poly (N-isopropylacrylamide) J. Macromol. Sci. Chem. 1968 2 1441 1455 10.1080/10601326808051910
  192. Kohori F. Sakai K. Aoyagi T. Yokoyama M. Sakurai Y. Okano T. Preparation and Characterization of Thermally Responsive Block Copolymer Micelles Comprising Poly(N-isopropylacrylamide-b-DL-lactide) J. Control. Release 1998 55 87 98 10.1016/S0168-3659(98)00023-6 9795019
  193. Wei H. Zhang X.-Z. Zhou Y. Cheng S.-X. Zhuo R.-X. Self-Assembled Thermoresponsive Micelles of Poly(N-isopropylacrylamide-b-methyl methacrylate) Biomaterials 2006 27 2028 2034 10.1016/j.biomaterials.2005.09.028
  194. Chung J.E. Yokoyama M. Yamato M. Aoyagi T. Sakurai Y. Okano T. Thermoresponsive Drug Delivery from Polymeric Micelles Constructed Using Block Copolymers of Poly(N-isopropylacrylamide) and Poly(butyl methacrylate) J. Control. Release 1999 62 115 127 10.1016/S0168-3659(99)00029-2 10518643
  195. Talelli M. Hennink W.E. Thermosensitive Polymeric Micelles for Targeted Drug Delivery Nanomedicine 2011 6 1245 1255 10.2217/nnm.11.91
  196. Kohori F. Sakai K. Aoyagi T. Yokoyama M. Yamato M. Sakurai Y. Control of Adriamycin Cytotoxic Activity Using Thermally Responsive Polymeric Micelles Composed of Poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-Poly(D,L-lactide) Colloids Surf. B Biointerfaces 1999 16 195 205 10.1016/S0927-7765(99)00070-3
  197. Liu S.Q. Tong Y.W. Yang Y.Y. Thermally Sensitive Micelles Self-Assembled from Poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-Poly(D,L-lactide-co-glycolide) for Controlled Delivery of Paclitaxel Mol. Biosyst. 2005 1 158 165 10.1039/b501756b
  198. Liu S.Q. Tong Y.W. Yang Y.Y. Incorporation and In Vitro Release of Doxorubicin in Thermally Sensitive Micelles Made from Poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-Poly(D,L-lactide-co-glycolide) with Varying Compositions Biomaterials 2005 26 5064 5074 10.1016/j.biomaterials.2005.01.030
  199. Topp M.D.C. Dijkstra P.J. Talsma H. Feijen J. Thermosensitive Micelle-Forming Block Copolymers of Poly(ethylene glycol) and Poly(N-isopropylacrylamide) Macromolecules 1997 30 8518 8520 10.1021/ma9710803
  200. Jamirad G. Seif M. Montazeri A. Fine-tuning hydrophilic–hydrophobic balance in stimuli-responsive PEG-PNIPAM micelles for controlled drug delivery J. Mol. Liq. 2025 436 128239 10.1016/j.molliq.2025.128239
  201. Cheng C. Wei H. Shi B.-X. Cheng H. Li C. Gu Z.-W. Cheng S.-X. Zhang X.-Z. Zhuo R.-X. Biotinylated Thermoresponsive Micelle Self-Assembled from Double-Hydrophilic Block Copolymer for Drug Delivery and Tumor Targeting Biomaterials 2008 29 497 505 10.1016/j.biomaterials.2007.10.004 17959241
  202. Dou J. Yu S. Reddy O. Zhang Y. Novel ABA Block Copolymers: Preparation, Temperature Sensitivity, and Drug Release RSC Adv. 2023 13 129 139 10.1039/D2RA05831F 36605663
  203. Yang X.-L. Luo Y.-L. Xu F. Chen Y.-S. Thermosensitive mPEG-b-PA-g-PNIPAM Comb Block Copolymer Micelles: Effect of Hydrophilic Chain Length and Camptothecin Release Behavior Pharm. Res. 2014 31 291 304 10.1007/s11095-013-1160-y
  204. Teotia A.K. Sami H. Kumar A. Thermo-Responsive Polymers Switchable and Responsive Surfaces and Materials for Biomedical Applications Woodhead Publishing Cambridge, UK 2015 3 43 10.1016/B978-0-85709-713-2.00001-8
  205. Kadam Y. Yerramilli U. Bahadur A. Bahadur P. Micelles from PEO–PPO–PEO Block Copolymers as Nanocontainers for Solubilization of a Poorly Water Soluble Drug Hydrochlorothiazide Colloids Surf. B Biointerfaces 2011 83 49 57 10.1016/j.colsurfb.2010.10.041
  206. Rey-Rico A. Cucchiarini M. PEO-PPO-PEO Tri-Block Copolymers for Gene Delivery Applications in Human Regenerative Medicine—An Overview Int. J. Mol. Sci. 2018 19 775 10.3390/ijms19030775
  207. Alakhov V. Klinski E. Li S. Pietrzynski G. Venne A. Batrakova E. Kabanov A. Block Copolymer-Based Formulation of Doxorubicin: From Cell Screen to Clinical Trials Colloids Surf. B Biointerfaces 1999 16 113 134 10.1016/S0927-7765(99)00064-8
  208. Alakhov V.Y. Moskaleva E.Y. Batrakova E.V. Kabanov A.V. Hypersensitization of Multidrug Resistant Human Ovarian Carcinoma Cells by Pluronic P85 Block Copolymer Bioconjug. Chem. 1996 7 209 216 10.1021/bc950093n
  209. Venne A. Li S. Mandeville R. Kabanov A. Alakhov V. Hypersensitizing Effect of Pluronic L61 on Cytotoxic Activity, Transport, and Subcellular Distribution of Doxorubicin in Multiple Drug-Resistant Cells Cancer Res. 1996 56 3626 3629 8705995
  210. Batrakova E.V. Dorodnych T.Y. Klinskii E.Y. Kliushnenkova E.N. Shemchukova O.B. Goncharova O.N. Arjakov S.A. Alakhov V.Y. Kabanov A.V. Anthracycline Antibiotics Non-Covalently Incorporated into Block Copolymer Micelles: In Vivo Evaluation of Anti-Cancer Activity Br. J. Cancer 1996 74 1545 1552 10.1038/bjc.1996.587
  211. Armstrong A. Brewer J. Newman C. Alakhov V. Pietrzynski G. Campbell S. Corrie P. Ranson M. Valle J.W. SP1049C as First-Line Therapy in Advanced (Inoperable or Metastatic) Adenocarcinoma of the Oesophagus: A Phase II Window Study J. Clin. Oncol. 2006 24 4080 10.1200/jco.2006.24.18_suppl.4080
  212. Chen L. Sha X. Jiang X. Chen Y. Ren Q. Fang X. Pluronic P105/F127 Mixed Micelles for the Delivery of Docetaxel against Taxol-Resistant Non-Small Cell Lung Cancer: Optimization and In Vitro, In Vivo Evaluation Int. J. Nanomed. 2013 8 73 84 10.2147/IJN.S38221
  213. Chen Y. Zhang W. Huang Y. Gao F. Sha X. Fang X. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor Int. J. Pharm. 2015 488 44 58 10.1016/j.ijpharm.2015.04.048
  214. Zhang W. Shi Y. Chen Y. Ye J. Sha X. Fang X. Multifunctional Pluronic P123/F127 Mixed Polymeric Micelles Loaded with Paclitaxel for the Treatment of Multidrug Resistant Tumors Biomaterials 2011 32 2894 2906 10.1016/j.biomaterials.2010.12.039 21256584
  215. Guo X. Li D. Yang G. Shi C. Tang Z. Wang J. Zhou S. Thermo-Triggered Drug Release from Actively Targeting Polymer Micelles ACS Appl. Mater. Interfaces 2014 6 8549 8559 10.1021/am501422r
  216. Gao H. Zhang J. Kleijn T.G. Wu Z. Liu B. Ma Y. Ding B. Yin D. Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases Oncol. Res. 2024 32 769 784 10.32604/or.2023.044276
  217. Cheng R. Meng F. Deng C. Klok H.-A. Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery Biomaterials 2013 34 3647 3657 10.1016/j.biomaterials.2013.01.084
  218. Hwang C. Sinskey A.J. Lodish H.F. Oxidized redox state of glutathione in the endoplasmic reticulum Science 1992 257 1496 1502 10.1126/science.1523409 1523409
  219. Tabatabaei Rezaei S.J. Sarbaz L. Niknejad H. Folate-decorated redox/pH dual-responsive degradable prodrug micelles for tumor-triggered targeted drug delivery RSC Adv. 2016 6 62630 62639 10.1039/C6RA11824K
  220. Teo J.Y. Chin W. Ke X. Gao S. Liu S. Cheng W. Hedrick J.L. Yang Y.Y. pH and redox dual-responsive biodegradable polymeric micelles with high drug loading for effective anticancer drug delivery Nanomedicine 2017 13 431 442 10.1016/j.nano.2016.09.016
  221. Chen W. Zhong P. Meng F. Cheng R. Deng C. Feijen J. Zhong Z. Redox and pH-responsive degradable micelles for dually activated intracellular anticancer drug release J. Control. Release 2013 169 171 179 10.1016/j.jconrel.2013.01.001
  222. Yang H.Y. Jang M.-S. Gao G.H. Lee J.H. Lee D.S. Construction of redox/pH dual stimuli-responsive PEGylated polymeric micelles for intracellular doxorubicin delivery in liver cancer Polym. Chem. 2016 7 1813 1825 10.1039/C5PY01808K
  223. Li B. Shan M. Di X. Gong C. Zhang L. Wang Y. Wu G. A dual pH- and reduction-responsive anticancer drug delivery system based on PEG–SS–poly(amino acid) block copolymer RSC Adv. 2017 7 30242 30249 10.1039/C7RA04254J
  224. Luo Y. Yin X. Yin X. Chen A. Zhao L. Zhang G. Liao W. Huang X. Li J. Zhang C.Y. Dual pH/Redox-Responsive Mixed Polymeric Micelles for Anticancer Drug Delivery and Controlled Release Pharmaceutics 2019 11 176 10.3390/pharmaceutics11040176
  225. Luo J. Zhang S. Zhu P. Liu W. Du J. Fabrication of pH/redox dual-responsive mixed polyprodrug micelles for improving cancer chemotherapy Front. Pharmacol. 2022 12 802785 10.3389/fphar.2021.802785 35185545
  226. Li Y. Hou H. Zhang P. Zhang Z. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual-responsive nanocarriers for osteosarcoma therapy Drug Deliv. 2020 27 1044 1053 10.1080/10717544.2020.1785049
  227. Zhang X. Wang Y. Wei G. Zhao J. Yang G. Zhou S. Stepwise dual targeting and dual responsive polymer micelles for mitochondrion therapy J. Control. Release 2020 322 157 169 10.1016/j.jconrel.2020.03.011
  228. Chen Y.-C. Liao L.-C. Lu P.-L. Lo C.-L. Tsai H.-C. Huang C.-Y. Wei K.-C. Yen T.-C. Hsiue G.-H. The accumulation of dual pH and temperature responsive micelles in tumors Biomaterials 2012 33 4576 4588 10.1016/j.biomaterials.2012.02.059
  229. Lei B. Sun M. Chen M. Xu S. Liu H. pH and temperature double-switch hybrid micelles for controllable drug release Langmuir 2021 37 14628 14637 10.1021/acs.langmuir.1c02298 34882421
  230. Hong W. Chen D. Jia L. Gu J. Hu H. Zhao X. Qiao M. Corrigendum to “Thermo- and pH-responsive copolymers based on PLGA-PEG-PLGA and poly(L-histidine): Synthesis and in vitro characterization of copolymer micelles” Acta Biomater. 2022 149 411 412 10.1016/j.actbio.2022.07.026
  231. Yang Z. Cheng R. Zhao C. Sun N. Luo H. Chen Y. Liu Z. Li X. Liu J. Tian Z. Thermo- and pH-dual responsive polymeric micelles with upper critical solution temperature behavior for photoacoustic imaging-guided synergistic chemo-photothermal therapy against subcutaneous and metastatic breast tumors Theranostics 2018 8 4097 4115 10.7150/thno.26195
  232. Lee S.W. Kim Y.M. Kim Y.T. Kang S.B. An open-label, multicenter, phase I trial of a Cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG-3016) J. Gynecol. Oncol. 2017 28 e26 10.3802/jgo.2017.28.e26 28028994
  233. Lee S.W. Kim Y.M. Cho C.H. Kim Y.T. Kim S.M. Hur S.Y. Kim J.H. Kim B.G. Kim S.C. Ryu H.S. et al. An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a Cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG-3021) Cancer Res. Treat. 2018 50 195 203 10.4143/crt.2016.376 28324920
  234. Kim D.W. Kim S.Y. Kim H.K. Kim S.W. Shin S.W. Kim J.S. Park K. Lee M.Y. Heo D.S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Oncol. 2007 18 2009 2014 10.1093/annonc/mdm374
  235. Keam B. Lee K.W. Lee S.H. Kim J.S. Kim J.H. Wu H.G. Eom K.Y. Kim S. Ahn S.H. Chung E.J. et al. A phase II study of Genexol-PM and cisplatin as induction chemotherapy in locally advanced head and neck squamous cell carcinoma Oncologist 2019 24 751-e231 10.1634/theoncologist.2019-0070
  236. Kim J.Y. Do Y.R. Song H.S. Cho Y.Y. Ryoo H.M. Bae S.H. Kim J.G. Chae Y.S. Kang B.W. Baek J.H. et al. Multicenter phase II clinical trial of Genexol-PM®with gemcitabine in advanced biliary tract cancer Anticancer Res. 2017 37 1467 1473 10.21873/anticanres.11471
  237. Kim H.S. Lee J.Y. Lim S.H. Sun J.M. Lee S.H. Ahn J.S. Park K. Moon S.H. Ahn M.J. A prospective phase II study of cisplatin and Cremophor EL-free paclitaxel (Genexol-PM) in patients with unresectable thymic epithelial tumors J. Thorac. Oncol. 2015 10 1800 1806 10.1097/JTO.0000000000000692
  238. Lee K.S. Chung H.C. Im S.A. Park Y.H. Kim C.S. Kim S.B. Rha S.Y. Lee M.Y. Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 2008 108 241 250 10.1007/s10549-007-9591-y
  239. Lee J.L. Ahn J.H. Park S.H. Lim H.Y. Kwon J.H. Ahn S. Song C. Hong J.H. Kim C.S. Ahn H. Phase II study of a Cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum Investig. New Drugs 2012 30 1984 1990 10.1007/s10637-011-9757-7
  240. Park I.H. Sohn J.H. Kim S.B. Lee K.S. Chung J.S. Lee S.H. Kim T.Y. Jung K.H. Cho E.K. Kim Y.S. et al. An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional Cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer Cancer Res. Treat. 2017 49 569 577 10.4143/crt.2016.289
  241. Kim J.Y. Lee E. Park K. Im S.A. Sohn J. Lee K.S. Chae Y.S. Kim J.H. Kim T.Y. Jung K.H. et al. Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11) Breast Cancer Res. Treat. 2019 178 367 377 10.1007/s10549-019-05400-y
  242. Online Database of Clinical Research Studies Available online: https://clinicaltrials.gov/ (accessed on 25 November 2025)
  243. Shi M. Sun J. Zhou J. Yu H. Yu S. Xia G. Wang L. Teng Y. Liu G. Yu C. et al. Phase I Dose Escalation and Pharmacokinetic Study on the Nanoparticle Formulation of Polymeric Micellar Paclitaxel for Injection in Patients with Advanced Solid Malignancies Investig. New Drugs 2018 36 269 277 10.1007/s10637-017-0506-4 28868573
  244. Gwak G. Chung M. Kim T.H. Park I. Kim J. Um E. Lee A. Kim J.I. A Multi-Center Trial to Evaluate the Safety and Toxicity of Nanoxel®-M in Breast Cancer Patients J. Breast Dis. 2021 9 45 55 10.14449/jbd.2021.9.2.45
  245. Matsumura Y. Hamaguchi T. Ura T. Muro K. Yamada Y. Shimada Y. Shirao K. Okusaka T. Ueno H. Ikeda M. et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 2004 91 1775 1781 10.1038/sj.bjc.6602204
  246. Kato K. Chin K. Yoshikawa T. Yamaguchi K. Tsuji Y. Esaki T. Sakai K. Kimura M. Hamaguchi T. Shimada Y. et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer Investig. New Drugs 2012 30 1621 1627 10.1007/s10637-011-9709-2
  247. Fujiwara Y. Mukai H. Saeki T. Ro J. Lin Y.C. Nagai S.E. Lee K.S. Watanabe J. Ohtani S. Kim S.B. et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients Br. J. Cancer 2019 120 475 480 10.1038/s41416-019-0391-z 30745582
  248. Burris H.A. Infante J.R. Anthony Greco F. Thompson D.S. Barton J.H. Bendell J.C. Nambu Y. Watanabe N. Jones S.F. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle Cancer Chemother. Pharmacol. 2016 77 1079 1086 10.1007/s00280-016-2986-x
  249. Hamaguchi T. Doi T. Eguchi-Nakajima T. Kato K. Yamada Y. Shimada Y. Fuse N. Ohtsu A. Matsumoto S.-I. Takanashi M. et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors Clin. Cancer Res. 2010 16 5058 10.1158/1078-0432.CCR-10-0387 20943763
  250. Jones S.F. Burris H.A. Infante J.R. Greco F.A. Spigel D.R. Kawamura S. Ishioka T. Yamazaki H. Bendell J.C. A phase I study of NK012 in combination with 5-fluorouracil with or without leucovorin in patients with advanced solid tumors J. Clin. Oncol. 2012 30 e13076 10.1200/jco.2012.30.15_suppl.e13076
  251. Ri M. Suzuki K. Iida S. Hatake K. Chou T. Taniwaki M. Watanabe N. Tsukamoto T. A phase I/II study for dose-finding, and to investigate the safety, pharmacokinetics and preliminary efficacy of NK012, an SN-38-incorporating macromolecular polymeric micelle, in patients with multiple myeloma Intern. Med. 2018 57 939 946 10.2169/internalmedicine.9567-17 29225263
  252. Hamaguchi T. Tsuji A. Yamaguchi K. Takeda K. Uetake H. Esaki T. Amagai K. Sakai D. Baba H. Kimura M. et al. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients Cancer Chemother. Pharmacol. 2018 82 1021 1029 10.1007/s00280-018-3693-6
  253. Doi T. Hamaguchi T. Shitara K. Iwasa S. Shimada Y. Harada M. Naito K. Hayashi N. Masada A. Ohtsu A. NC-6004 phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis Cancer Chemother. Pharmacol. 2017 79 569 578 10.1007/s00280-017-3254-4
  254. Subbiah V. Grilley-Olson J.E. Combest A.J. Sharma N. Tran R.H. Bobe I. Osada A. Takahashi K. Balkissoon J. Camp A. et al. Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors Clin. Cancer Res. 2018 24 43 51 10.1158/1078-0432.CCR-17-1114
  255. Volovat S.R. Ciuleanu T.E. Koralewski P. Olson J.E.G. Croitoru A. Koynov K. Stabile S. Cerea G. Osada A. Bobe I. et al. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer Oncotarget 2020 11 3105 3117 10.18632/oncotarget.27684
  256. Danson S. Ferry D. Alakhov V. Margison J. Kerr D. Jowle D. Brampton M. Halbert G. Ranson M. Phase I dose escalation and pharmacokinetic study of Pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer Br. J. Cancer 2004 90 2085 2091 10.1038/sj.bjc.6601856
  257. Valle J.W. Armstrong A. Newman C. Alakhov V. Pietrzynski G. Brewer J. Campbell S. Corrie P. Rowinsky E.K. Ranson M. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting Pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction Investig. New Drugs 2011 29 1029 1037 10.1007/s10637-010-9399-1
  258. Mukai H. Kogawa T. Matsubara N. Naito Y. Sasaki M. Hosono A. A first-in-human phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors Investig. New Drugs 2017 35 307 314 10.1007/s10637-016-0422-z 28054329
  259. Von Hoff D.D. Mita M.M. Ramanathan R.K. Weiss G.J. Mita A.C. LoRusso P.M. Burris H.A. III Hart L.L. Low S.C. Parsons D.M. et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors Clin. Cancer Res. 2016 22 3157 3163 10.1158/1078-0432.CCR-15-2548
  260. Autio K.A. Garcia J.A. Alva A.S. Hart L.L. Milowsky M.I. Posadas E.M. Ryan C.J. Summa J.M. Youssoufian H. Scher H.I. et al. A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) J. Clin. Oncol. 2016 34 233 10.1200/jco.2016.34.2_suppl.233
  261. Autio K.A. Dreicer R. Anderson J. Garcia J.A. Alva A. Hart L.L. Milowsky M.I. Posadas E.M. Ryan C.J. Graf R.P. et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial JAMA Oncol. 2018 4 1344 1351 10.1001/jamaoncol.2018.2168 29978216
  262. Saeki T. Mukai H. Ro J. Lin Y.C. Fujiwara Y. Nagai S. Lee K.S. Watanabe J. Ohtani S. Kim S.B. et al. A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients Ann. Oncol. 2017 28 v80 v81 10.1093/annonc/mdx365.013
  263. Chawla S.P. Goel S. Chow W. Braiteh F. Singh A.S. Olson J.E.G. Osada A. Bobe I. Riedel R.F. A phase 1b dose escalation trial of NC-6300 (nanoparticle epirubicin) in patients with advanced solid tumors or advanced, metastatic, or unresectable soft-tissue sarcoma Clin. Cancer Res. 2020 26 4225 4232 10.1158/1078-0432.CCR-20-0591 32381487
  264. Hrkach J. Von Hoff D. Mukkaram Ali M. Andrianova E. Auer J. Campbell T. De Witt D. Figa M. Figueiredo M. Horhota A. et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 2012 4 128ra39 10.1126/scitranslmed.3003651
  265. Azimi S. Intelligent nanoparticle design: Unlocking the potential of AI for transformative drug delivery Curr. Opin. Biomed. Eng. 2025 36 100625 10.1016/j.cobme.2025.100625

Issue

Pharmaceutics, vol. 18, 2026, Switzerland, https://doi.org/10.3390/pharmaceutics18020177

Вид: статия в списание, публикация в издание с импакт фактор, публикация в реферирано издание, индексирана в Scopus